Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)

Phase 2 Not yet recruiting 35 enrolled Sun Yat-sen University

NaSingle-groupOpen-labelTreatment

Summary

This study will treat patients with newly diagnosed PTCL, who have no prior systemic treatment for T-cell lymphoma. This study will assess the anti-tumor efficacy of golidocitinib using 2-year Progression-Free Survival rate as primary endpoint. In addition, it will help to understand what type of side effects may occur with the drug treatment.

Timeline

Start: 2025-07
Primary completion: 2028-12
Completion: 2028-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Golidocitinib	Small molecule	150 mg	Oral
Background	Cyclophosphamide	Other / unclassified	750 mg/m2	Intravenous
Background	Doxorubicin	Other / unclassified	50 mg/m2	Intravenous
Background	Prednisone	Other / unclassified	100 mg	Oral
Background	Vincristine	Small molecule	1.4 mg/m2	Intravenous

Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)

Summary

Timeline

Drugs

Indications